The Future of
Drug Discovery is Here.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Who We Are
Duis irure dolor reprehenderit
in voluptate velit esse cillum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse.
What We Do
Duis irure dolor reprehenderit
in voluptate velit esse cillum
High-Throughput Screening
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
High-Throughput Screening
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
High-Throughput Screening
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Client Outcomes
Duis irure dolor reprehenderit
in voluptate velit esse cillum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse.
News
Duis irure dolor reprehenderit
in voluptate velit esse cillum
A co-authored paper by researcher Miura of the DMPK & Safety Business Unit was published in Metabolites
Investigation of storage conditions and quality control markers for metabolites and lipids in human feces Publication Published...
A paper by researcher Hitaka of the Pharmacology Business Unit has been published in the International Journal of Obesity.
Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison Publication...
Nissan Chemical and Axcelead DDP Enter into License Agreement for DNA-Encoded Library (DEL)
Tokyo and Fujisawa, Japan – February 24, 2026 – Nissan Chemical Corporation (Headquarter: Tokyo, Japan;...